Literature DB >> 2515555

Myocardial infarction and antiphospholipid antibodies in SLE and related disorders.

R A Asherson1, M A Khamashta, E Baguley, C M Oakley, N R Rowell, G R Hughes.   

Abstract

The clinical and serological findings in 13 patients with myocardial infarction and antiphospholipid antibodies (the 'lupus anticoagulant', antibodies to cardiolipin, antibodies to phosphatidylethanolamine (one patient] seen by our unit and other units from 1984 to 1989, are presented (eight males and five females, ages ranging from 20 to 52 years). Five suffered myocardial infarction before the age of 30; four of these five were in their early 20s. Other risk factors such as excessive smoking (greater than 20 cigarettes a day) (two patients), long-term treatment with steroid (one) and use of oral contraceptives (one) were present. One patient had demonstrated a plasminogen activator deficiency and one a deficiency of protein C. Two patients developed myocardial infarction six to eight weeks after warfarin was discontinued for recurrent deep vein thrombosis. Six patients had SLE as defined by the revised 1982 criteria, three suffered from 'lupus-like' disease, while four patients conformed to a 'primary' antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515555

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  12 in total

Review 1.  Antiphospholipid antibodies and cardiovascular disease.

Authors:  H L Beynon; M J Walport
Journal:  Br Heart J       Date:  1992-04

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 3.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Hypertrophic cardiomyopathy and systemic lupus erythematosus.

Authors:  J Ara; J Vivancos; J Soler-Carrillo; J C Paré; R Cervera; J Font
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 5.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

6.  Antiphospholipid antibodies, lupus-like disease and the "primary" antiphospholipid syndrome.

Authors:  R A Asherson; M A Khanashta; G R Hughes
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

7.  Coronary steal due to ruptured right coronary aneurysm causing myocardial infarction in a patient with systemic lupus erythematosus.

Authors:  Kazuhito Hirata; Nobuhito Yagi; Minoru Wake; Takanori Takahashi; Jun Nakazato; Tadayoshi Miyagi; Junichi Shimotakahara
Journal:  Cardiovasc Diagn Ther       Date:  2014-08

Review 8.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

Review 9.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

10.  Atherosclerotic vascular disease in systemic lupus erythematosus.

Authors:  Matthew H Liang; Lisa A Mandl; Karen Costenbader; Ervin Fox; Elizabeth Karlson
Journal:  J Natl Med Assoc       Date:  2002-09       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.